Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Gynecology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 103 articles:
HTML format



Single Articles


    November 2023
  1. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    PubMed    


  2. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available


  3. HOBSON G, Dennis N
    Experiences of menopause in the Welsh NHS workplace: a focus group study.
    Lancet. 2023;402 Suppl 1:S51.
    PubMed     Abstract available


  4. JONG FC, Kotzur M, Amiri R, Ling J, et al
    Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.
    Lancet. 2023;402 Suppl 1:S12.
    PubMed     Abstract available


  5. COWLING A, Nevens L, Contogiorgi N, Bradley N, et al
    Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S35.
    PubMed     Abstract available


    October 2023
  6. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    


  7. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available


  8. BHAN N, McDougal L
    Centring agency and norms to meet the health needs of pregnant adolescents.
    Lancet. 2023 Oct 11:S0140-6736(23)02226-2. doi: 10.1016/S0140-6736(23)02226.
    PubMed    


  9. SABET F, Prost A, Rahmanian S, Al Qudah H, et al
    The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.
    Lancet. 2023 Oct 11:S0140-6736(23)01682-3. doi: 10.1016/S0140-6736(23)01682.
    PubMed     Abstract available


    August 2023
  10. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    PubMed    


  11. JAFFE S
    Abortion foes threaten PEPFAR.
    Lancet. 2023;402:598.
    PubMed    


  12. CAHILL EP
    Adding a COX-2 inhibitor improves efficacy of emergency contraception.
    Lancet. 2023 Aug 16:S0140-6736(23)01612-4. doi: 10.1016/S0140-6736(23)01612.
    PubMed    


  13. LI RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, et al
    Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet. 2023 Aug 16:S0140-6736(23)01240-0. doi: 10.1016/S0140-6736(23)01240.
    PubMed     Abstract available


    July 2023
  14. DASGUPTA N, Ajazi EM, Schwartz TA, Marshall SW, et al
    Misclassification of overdose events in the X:BOT study.
    Lancet. 2023 Jul 19:S0140-6736(23)00113-7. doi: 10.1016/S0140-6736(23)00113.
    PubMed    


  15. SABBAH N, Demar M, Sogbo F, Zappa M, et al
    Recurrent vomiting and confusion in pregnancy: hypercalcaemia due to parathyroid adenoma.
    Lancet. 2023;402:62-63.
    PubMed    


  16. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    PubMed    


    June 2023
  17. CLUVER CA, Walker SP
    Early delivery for pre-eclampsia might save lives in low-income and middle-income settings.
    Lancet. 2023 Jun 29:S0140-6736(23)00824-3. doi: 10.1016/S0140-6736(23)00824.
    PubMed    


  18. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    PubMed     Abstract available


  19. LUCAS DN, Bamber JH, Quasim S
    Perinatal outcomes and the role of obstetric anaesthesia interventions.
    Lancet. 2023;401:2038-2039.
    PubMed    


  20. QUENBY S, Booth K, Hiller L, Coomarasamy A, et al
    Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
    Lancet. 2023 Jun 1:S0140-6736(23)00693-1. doi: 10.1016/S0140-6736(23)00693.
    PubMed     Abstract available


    May 2023
  21. SHAHEEN-HUSSAIN S, Lombard A, Basile S
    Confronting medical colonialism and obstetric violence in Canada.
    Lancet. 2023;401:1763-1765.
    PubMed    


  22. MCCURRY J
    Japan approves abortion pill.
    Lancet. 2023;401:1558.
    PubMed    


  23. MOHIDDIN A, Semrau KEA, Simon J, Langlois EV, et al
    The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response.
    Lancet. 2023 May 5:S0140-6736(23)00721-3. doi: 10.1016/S0140-6736(23)00721.
    PubMed    


    April 2023
  24. HEISLER M, Cox-Toure T, Kaufman R
    US abortion bans violate patients' right to information and to health.
    Lancet. 2023 Apr 24:S0140-6736(23)00808-5. doi: 10.1016/S0140-6736(23)00808.
    PubMed    


  25. JAFFE S
    Drug developers caution against US mifepristone ban.
    Lancet. 2023;401:1325-1326.
    PubMed    


  26. SHAND AW, Kidson-Gerber GL
    Anaemia in pregnancy: a major global health problem.
    Lancet. 2023 Apr 20:S0140-6736(23)00396-3. doi: 10.1016/S0140-6736(23)00396.
    PubMed    


  27. PASRICHA SR, Mwangi MN, Moya E, Ataide R, et al
    Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00278-7. doi: 10.1016/S0140-6736(23)00278.
    PubMed     Abstract available


  28. CHANDYO RK, Kvestad I, Ulak M, Ranjitkar S, et al
    The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
    Lancet. 2023 Apr 6:S0140-6736(23)00346-X. doi: 10.1016/S0140-6736(23)00346.
    PubMed     Abstract available


    March 2023
  29. BERGH C, Lundin K
    No benefit to pregnancy or livebirth by time-lapse-based embryo selection in IVF.
    Lancet. 2023 Mar 30:S0140-6736(23)00219-2. doi: 10.1016/S0140-6736(23)00219.
    PubMed    


  30. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
    Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
    PubMed     Abstract available


  31. PRAGUE JK
    Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
    Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
    PubMed    


  32. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
    Lancet. 2023;401:856-857.
    PubMed    


  33. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
    The need for appropriate language in the debate on medicalisation of pregnancy.
    Lancet. 2023;401:818-819.
    PubMed    


  34. KAKURU A, Jagannathan P
    Can we reduce malaria in pregnancy and improve birth outcomes?
    Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
    PubMed    


  35. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
    Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
    Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
    PubMed     Abstract available


  36. HAWKES S, Kedia S, Odunga S, Dahal M, et al
    From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
    Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
    PubMed    


    February 2023
  37. MURRAY CJL
    A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
    Lancet. 2023;401:555-556.
    PubMed    


  38. JACKSON A
    A systematic analysis points in the wrong direction for cervical cancer elimination.
    Lancet. 2023;401:555.
    PubMed    


  39. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    PubMed    


  40. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    PubMed     Abstract available


  41. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    PubMed     Abstract available


  42. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    PubMed    


    January 2023
  43. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    PubMed    


  44. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available


    December 2022
  45. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    PubMed     Abstract available


    November 2022
  46. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    PubMed     Abstract available


  47. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    PubMed    


  48. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    PubMed     Abstract available


  49. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    PubMed     Abstract available


    October 2022
  50. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    PubMed    


  51. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    PubMed    


  52. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    PubMed    


  53. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    PubMed    


  54. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    PubMed     Abstract available


  55. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    PubMed     Abstract available


  56. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    PubMed    


  57. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    PubMed    


    September 2022
  58. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    PubMed     Abstract available


  59. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    PubMed    


    August 2022
  60. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    PubMed     Abstract available


  61. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    PubMed    


  62. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    PubMed    


    July 2022
  63. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    PubMed     Abstract available


  64. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    PubMed    


  65. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    PubMed    


  66. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    PubMed    


  67. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    PubMed    


    June 2022
  68. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    PubMed    


  69. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    PubMed     Abstract available


  70. SARASWAT L, Bhattacharya S
    Relugolix combination therapy for endometriosis pain.
    Lancet. 2022;399:2244-2245.
    PubMed    


  71. HOLT E
    Poland to introduce controversial pregnancy register.
    Lancet. 2022;399:2256.
    PubMed    


  72. THE LANCET
    Attitudes towards menopause: time for change.
    Lancet. 2022;399:2243.
    PubMed    


  73. O'BRIEN E, Rich M
    Obstetric violence in historical perspective.
    Lancet. 2022;399:2183-2185.
    PubMed    


  74. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
    Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
    Lancet. 2022;399:2103-2112.
    PubMed     Abstract available


  75. BARTZ D
    Incidence of perforation with intrauterine devices.
    Lancet. 2022;399:2076-2077.
    PubMed    


    May 2022
  76. SCHAEDEL Z, Rymer J
    Menopause care and over the counter vaginal oestradiol.
    Lancet. 2022 May 31. pii: S0140-6736(22)00952.
    PubMed    


  77. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
    Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
    Lancet. 2022;399:2014.
    PubMed    


  78. RAVI K, Janiak E
    Adverse pregnancy outcomes: biological essentialism versus embodied biology.
    Lancet. 2022;399:2013-2014.
    PubMed    


  79. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    PubMed    


  80. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    PubMed    


  81. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    PubMed    


  82. JAFFE S
    Health organizations fear effects of US abortion ruling.
    Lancet. 2022;399:1854.
    PubMed    


  83. VOSS FO, van Beurden M, Jordanova ES
    Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
    Lancet. 2022;399:1755-1757.
    PubMed    


  84. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
    Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2022;399:1790-1798.
    PubMed     Abstract available


  85. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    PubMed    


    April 2022
  86. MAKONI M
    Hope for access to abortion in Kenya.
    Lancet. 2022;399:1456.
    PubMed    


  87. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    PubMed     Abstract available


    March 2022
  88. BOOTH A
    Activists welcome Colombia's decriminalisation of abortion.
    Lancet. 2022;399:899.
    PubMed    


  89. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    PubMed    


    February 2022
  90. PASHANKAR R, Prabulos AM, Feder HM Jr
    A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
    Lancet. 2022;399:e10.
    PubMed    


  91. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    PubMed    


  92. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
    Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Lancet. 2022;399:541-553.
    PubMed     Abstract available


  93. BLAGDEN SP
    Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Lancet. 2022;399:499-501.
    PubMed    


  94. CERDEIRA AS, Ismail L, Moore N, George B, et al
    Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
    Lancet. 2022;399:554.
    PubMed    


    January 2022
  95. HUG L, You D, Blencowe H, Moran AC, et al
    Strengthening the reporting of stillbirths globally - Authors' reply.
    Lancet. 2022;399:142.
    PubMed    


  96. DAS AM, Janardhanan R
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:141.
    PubMed    


  97. JOOS O, Swiney C, Sferrazza L
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:140-141.
    PubMed    


    December 2021
  98. JAFFE S
    US Supreme Court expected to weaken abortion rights.
    Lancet. 2021;398:2137-2138.
    PubMed    


    November 2021
  99. SANSON C, Majer M, Pautier P, Gouy S, et al
    Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
    Lancet. 2021;398:e17.
    PubMed    


  100. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available


  101. CRUICKSHANK ME, Grigore M
    Cervical cancers avoided by HPV immunisation.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
    PubMed    


  102. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
    Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
    Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
    PubMed     Abstract available


    October 2021
  103. THE LANCET
    Abortion bans in the USA harm health equity.
    Lancet. 2021;398:1461.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.